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Abstract
The objective of this study was to determine the appropriate dose of artesunate for use in a fixed dose combination therapy
with chlorproguanil2dapsone (CPG2DDS) for the treatment of uncomplicated falciparum malaria.Methods: Open-label
clinical trial comparing CPG2DDS alone or with artesunate 4, 2, or 1 mg/kg at medical centers in Blantyre, Malawi and
Farafenni, The Gambia. The trial was conducted between June 2002 and February 2005, including 116 adults (median age
27 years) and 107 children (median age 38 months) with acute uncomplicated Plasmodium falciparum malaria. Subjects
were randomized into 4 groups to receive CPG–DDS alone or plus 4, 2 or 1 mg/kg of artesunate once daily for 3 days.
Assessments took place on Days 023 in hospital and follow-up on Days 7 and 14 as out-patients. Efficacy was evaluated in
the Day 3 per-protocol (PP) population using mean time to reduce baseline parasitemia by 90% (PC90). A number of
secondary outcomes were also included. Appropriate artesunate dose was determined using a pre-defined decision matrix
based on primary and secondary outcomes. Treatment emergent adverse events were recorded from clinical assessments
and blood parameters. Safety was evaluated in the intent to treat (ITT) population.
Results: In the Day 3 PP population for the adult group (N= 85), mean time to PC90 was 19.1 h in the CPG2DDS group,
significantly longer than for the +artesunate 1 mg/kg (12.5 h; treatment difference 26.6 h [95%CI 211.8, 21.5]), 2 mg/kg
(10.7 h;28.4 h [95%CI213.6,23.2]) and 4 mg/kg (10.3 h;28.7 h [95%CI214.1,23.2]) groups. For children in the Day 3 PP
population (N = 92), mean time to PC90 was 21.1 h in the CPG2DDS group, similar to the +artesunate 1 mg/kg group
(17.7 h; 23.3 h [95%CI 28.6, 2.0]), though the +artesunate 2 mg/kg and 4 mg/kg groups had significantly shorter mean
times to PC90 versus CPG2DDS; 14.4 h (treatment difference 26.4 h [95%CI 211.7, 21.0]) and 12.8 h (27.4 h [95%CI
212.9,21.8]), respectively. An analysis of mean time to PC90 for the Day 14 PP and ITT populations was consistent with the
primary analysis. Treatment emergent, drug-related adverse events were experienced in 35.3% (41/116) of adults and 70.1%
(75/107) of children; mostly hematological and gastroenterological. The nature and incidence of adverse events was similar
between the groups. No dose-related changes in laboratory parameters were observed. Nine serious adverse events due to
any cause occurred in five subjects including two cases of hemolysis believed to be associated with drug treatment (one
adult, one child). One adult died of anaphylactic shock, not associated with investigational therapy.
Conclusions: CPG–DDS plus artesunate demonstrated advantages over CPG–DDS alone for the primary efficacy endpoint
(mean time to PC90) except in children for the 1 mg/kg artesunate dose. Based on a pre-defined decision matrix, the
primary endpoint in the child group supported an artesunate dose of 4 mg/kg. Secondary endpoints also supported a
4 mg/kg artesunate dose to take forward into the remainder of the development program.
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Introduction
Over one million people die of malaria every year, mostly
children [1]. Widespread drug resistance in Plasmodium spp. has
undermined the effectiveness of many of the antimalarials used
commonly, particularly chloroquine [2]. Combination therapy is
required to combat these resistant strains and preserve antimala-
rial effectiveness. It is important that new combinations include
agents with different mechanisms of action used at appropriate
doses to ensure maximal and rapid parasite killing.
In consideration of these points, in 2004 the World Health
Organization (WHO) Roll Back Malaria group recommended that
first-line treatment of uncomplicated malaria should be with
artemisinin-based combination therapy [3]. Artemisinin-derived
drugs such as artesunate and artemether are effective against
multi-drug resistant strains of P. falciparum [4,5], and are highly
potent against asexual forms, rapidly reducing parasitemia [6,7].
In addition, these agents are active against gametocytes,
potentially reducing transmission rates [8–12]. Current evidence
suggests that these agents are well tolerated in humans at doses
under 15 mg/kg, though they are contra-indicated in early
pregnancy [13]. However, effective monotherapy requires seven
days of treatment, increasing the risk of resistance development
through poor compliance and so these agents must be combined
with at least one other antimalarial.
Chlorproguanil2dapsone (CPG2DDS, LapdapTM) was devel-
oped through a public2private partnership as a low-cost, fixed
dose combination for the treatment of uncomplicated malaria due
to Plasmodium falciparum [14]. In a study of 1850 children from five
African countries, CPG2DDS had greater efficacy than sulfadox-
ine-pyrimethamine and was generally well tolerated, though
hematological adverse effects were more common in the CPG–
DDS group [15]. CPG–DDS is rapidly eliminated and has been
shown to exert a reduced selective pressure for resistance on P.
falciparum compared with the more slowly eliminated combination
sulfadoxine-pyrimethamine with no increase in the incidence of
retreatment [16,17].
A clinical program to develop CPG2DDS2artesunate (CDA)
is currently in progress. CDA is an interesting combination for
investigation as the three compounds have well-matched pharma-
cokinetics, i.e. all are relatively rapidly eliminated. Thus, there is a
reduced risk of parasite exposure to any single compound after
elimination of the partner drug, potentially decreasing the risk of
resistance emergence.
This study was a phase II trial to determine the most
appropriate dose of artesunate for use in combination with
CPG–DDS. Four dosing groups were included: CPG–DDS alone
or with 4, 2, or 1 mg/kg artesunate. The WHO-defined ‘adequate
clinical and parasitological response’ with CPG–DDS alone has
been reported as 96% in African children at 14-days’ follow up
[15]. Owing to this high efficacy rate, it would be impractical to
determine any additional efficacy with artesunate over
CPG2DDS alone using this outcome measure in a four arm
study.
As artesunate rapidly clears parasites from the blood, the
protocol development committee concluded that parasitemia-
derived indices of therapeutic response, in particular time to
reduce parasitemia by 90%, would be the most relevant alternative
outcomes to detect differences between the artesunate dose groups
and CPG2DDS alone. A suite of other outcomes was also
included. Children are the primary population of interest because
of the higher mortality risk compared with adults [1]. However, to
determine drug effects on parasitemia, frequent blood sampling is
required over the first 48 h after dosing. Owing to the difficulties
of conducting the repeat sampling required in children, adults
were also included in the study to provide a more complete set of
time points for modeling the change in parasite counts over time.
This novel study design was a pragmatic approach to evaluating
the possible differential effect of adding artesunate at three doses to
CPG2DDS in children and adults. The aim of the trial was to
determine the dose of artesunate that would be included in the
CDA fixed dose combination for further testing in Phase III
studies.
Methods
Participants
This study was conducted in accordance with the International
Conference on Harmonization Good Clinical Practice Guidelines
and all applicable regulatory requirements and the guiding
principles of the Declaration of Helsinki. Participants were
recruited under a human use protocol approved by and executed
in accordance with the ethics committees of the Malawi College of
Medicine, the Joint Gambian Government/Medical Research
Council and the Liverpool School of Tropical Medicine. The
CONSORT checklist and trial protocol for this paper are
available as supporting information; see Checklist S1 and Protocol
S1.
Eligible participants included adults aged 18260 years or
children aged 122120 months presenting to a healthcare facility
with probable uncomplicated clinical malaria. Inclusion criteria
were: weight between 5 and 85 kg; and presence of P. falciparum
asexual parasitemia, based on microscopic screening of stained
blood films at a density of 10,0002100,000 mL21 in adults and
25,0002100,000 mL21 in children. All patients or their parent/
guardian provided written or oral witnessed consent and agreed to
comply with the requirements of the protocol. A negative
pregnancy test was required for all women $12 years of age on
enrolment.
Subjects were excluded from the study if they had features of
severe or complicated falciparum malaria, a known allergy to
sulphonamides, evidence of any concomitant infection at the time
of presentation (including P. ovale and P. malariae parasitemia) or
any other underlying disease that would compromise the diagnosis
and the evaluation of the response to the study medication
(including clinical symptoms of immunosuppression, tuberculosis
or bacterial infection). Women who had a positive pregnancy test,
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did not take a pregnancy test or were breastfeeding during the
study were also excluded.
Subjects were also excluded if they had received treatment with:
a sulphonamide antimalarial or chloroquine within 28 days prior
to screening; mefloquine within 21 days prior to screening;
amodiaquine, halofantrine, quinine (full course), atovaquone2-
proguanil, artemisinins, co-artemether, tetracycline or clindamy-
cin within 7 days prior to screening; or treatment for 5 half-lives
prior to screening with drugs that have potential antimalarial
activity. In addition, subjects could not have used an investiga-
tional drug within 30 days or 5 half-lives (whichever was
longer) prior to screening, or participated previously in the
current study.
Interventions
A full history and examination was performed at the initial
patient assessment. Study participants who fulfilled the inclusion/
exclusion criteria were randomized to one of four treatment
groups: CPG–DDS alone; CPG2DDS plus 4 mg/kg artesunate;
CPG2DDS plus 2 mg/kg artesunate or; CPG2DDS plus 1 mg/
kg artesunate. CPG2DDS was provided as LapdapTM 15/
18.75 mg or 80/100 mg tablets (Wulfing Pharma, Gronau,
Germany) and patients were given half, one, one and a half or
two tablets to achieve a target dose as close as possible to 2 mg/kg
CPG and 2.5 mg/kg DDS. Artesunate was provided as 1 mg,
10 mg, 25 mg or 50 mg tablets (Abbott Laboratories, Liestal,
Switzerland). All drug treatments were administered according to
predefined dosing charts.
All patients received study drug once daily for 3 days (Days 0, 1,
2), during which time they were hospitalized for study-related
procedures. Patients were discharged from hospital on Day 3 and
asked to return for outpatient follow-up visits on Days 7 and 14.
Blood samples for parasitemia blood slide (10 mL) were obtained
from adults via cannula for the first 24 h and by venepuncture
thereafter and from children using finger-prick. In adults, sampling
was performed on Day 0 at the time of first drug dose then at 1, 2,
3, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and 72 h during therapy. In
children, blood samples were collected at the time of first dose and
at 6, 12, 18, 24, 36, 42, 48 and 72 h during therapy. Samples were
also collected from all patients at the follow up visits on Days 7 and
14.
For other outcomes, a 100 mL blood sample was taken at Day 0
at the time of first study dose in adults and children then at 1, 2, 4,
8, 12 and 24 h during therapy in adults and at 12 h only in
children. The 12-h sample was the key timepoint used for the
parasite viability assessment.
Samples for biochemical and hematological analysis (2 mL of
blood), including reticulocyte analysis, were taken on Day 0, Day 3
and Day 7 from all patients and on Day 14 if any value was
abnormal on Day 7. Samples were analyzed locally at each
investigational center.
Objectives
The objective of this trial was to determine the most appropriate
dose of artesunate to use in combination with CPG–DDS for the
treatment of uncomplicated P. falciparum malaria.
Outcomes
The primary endpoint was the mean time to achieve a 90%
reduction in parasitemia versus baseline (PC90), determined from
Giemsa-stained blood smears. The quality-control procedure for
conducting the slide counts involved checking every seventh or
tenth slide and eliciting an additional expert reading in the event
of significant discrepancies. Screening parasitemia density was
calculated using the nominal white blood cell count (WBC) value
of 8,000 mL21, according to WHO protocol WHO/HTM/
RBM/2003.50 [18]. The actual density of parasitemia was
determined by correcting for the WBC for each subject once the
hematology results were available. The actual parasitemia value
was used as the baseline level for all outcome assessments.
Parasite viability was considered a key secondary endpoint;
defined as the percentage of ring-form parasites obtained from the
patient 12 h after the first dose of study drug that developed into
trophozoites when cultured in vivo. It was determined using the
method of Murphy, et al. [19]. Briefly, 100 mL venous blood
samples were collected 12 h after the first dose of study drug.
Parasite development was continued ex-vivo by inoculating blood
samples into culture medium and incubating at 37uC for 48 h by
which time all viable ring-form parasites should have matured into
late trophozoites. Growth was arrested at this phase by inclusion of
aphidicolin in the culture medium. The proportion of ring-form
parasites and trophozoites on blood slides from the cultured
samples was then compared with slides made from the same blood
sample immediately after collection.
The mean time to achieve a 99% reduction (PC99) and 50%
reduction (PC50) in parasitemia versus baseline were also included
as secondary outcomes and calculated using similar methods as
mean time to PC90. Slides prepared for parasitology were also
read for the presence or absence of gametocytes per 200 white
blood cells at baseline and Days 3, 7 and 14.
The number of early or late treatment failures based on the
WHO 2002 definitions was also determined [20]. In brief, early
treatment failure is a clinical or parasitological failure occurring
within 96 h of the start of therapy and late clinical or
parasitological failure is defined as occurring after this time and
before Day 14. Adequate clinical and parasitological response
(ACPR) is the absence of parasitemia on Day 14, irrespective of
axillary temperature, without previous treatment failure. Recru-
descence was distinguished from new infection using msp1 and
msp2 polymerase chain reaction genotyping [21]. ACPR was
expressed as corrected for these results (ACPRp), to include
patients who were late clinical and/or parasitological failures but
who had a new infection and no recrudescence of the original
infection.
Outcome decision matrix. The most appropriate dose of
artesunate was determined according to a pre-defined decision
matrix, summarized as:
i) Choose 2 mg/kg artesunate if all artesunate groups
have efficacy greater than CPG–DDS alone and there is
no difference in the primary endpoint or any other
difference in efficacy or safety between the artesunate
treatment groups versus CPG2DDS alone.
ii) Choose 4 mg/kg artesunate if 1 mg/kg or 2 mg/kg
do not have greater efficacy than CPG2DDS alone for
the primary endpoint or if there is a difference in the
primary endpoint or any other efficacy or safety
endpoint between the artesunate 4 mg/kg and the 1
or 2 mg/kg groups versus CPG2DDS alone (in favor of
the 4 mg/kg artesunate dose).
In addition, if data from the clinically more vulnerable child
group suggested a higher artesunate dose than data from adults,
then the higher dose would be chosen. The rationale for the design
of the outcome decision matrix can be found in the Discussion
section of this paper.
Safety. Adverse events and severity (graded as mild, moderate
or severe) were determined by the investigators and defined as any
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untoward medical occurrence temporally associated with the use
of study drug, whether or not considered to be related to the study
drug. Adverse events were recorded and coded using the latest
version of MedDRA. Lack of efficacy was not included as an
adverse event per se except for the development of clinically severe
malaria, including a parasite count of .250,000 mL21 and severe
anemia (hemoglobin ,5.0 g/dL).
A serious adverse event was defined as one which resulted in
death, was life-threatening, resulted in hospitalization or prolon-
gation of hospitalization, was disabling, a congenital anomaly or
any other event considered significant by the investigator. The
investigator was to follow all serious adverse events until
resolution, the condition stabilized, the event was otherwise
explained or the subject was lost to follow-up.
Sample size
A sample size of eighty-eight evaluable subjects (22 per
treatment group) would provide 90% power at a 5% two-sided
significance level to detect a difference of 9 h in the mean time to
PC90 between the groups treated with CPG2DDS plus 4, 2, or
1 mg/kg of artesunate versus CPG–DDS alone. Allowing for a
25% drop-out rate, a target sample size of 120 adults and 120
children was calculated.
The adult group was stratified by gender to prevent a bias. The
child group was stratified by age to ensure that both younger and
older children were represented.
Randomization2Sequence generation
The randomization code was generated by computer at
GlaxoSmithKline, Greenford, UK. Different codes were allocated
for adult sex strata and child age strata and distributed using
scratch cards bearing unique study numbers.
Randomization2Allocation concealment
This was an open-label study.
Randomization2Implementation
Scratch cards were provided to clinicians and were selected
consecutively on patient enrolment to reveal treatment allocation.
Blinding
In order to achieve accurate artesunate dosing, this study was
conducted open label to the treating physician and nursing staff.
However, the technicians performing the slide reading and
parasite viability analysis were blinded to the treatment group.
Subjects assigned to receive CPG2DDS alone did not receive
placebo to replace artesunate.
Statistical methods
The intent to treat (ITT) population included all randomized
subjects who received at least one dose of study medication. The
per-protocol (PP) population was a sub-set of the ITT population
including those patients who were compliant with all doses of study
medication, had no major protocol violations, took no prohibited
concomitant medications during the treatment period and had a
baseline actual parasitemia level of $5,000 mL21 for adults and
$12,500 mL21 for children.
The primary analysis was conducted on the Day 3 PP
population who had completed all visits through to the assessment
at Day 3. Additional sensitivity analyses were prepared using the
ITT population and the Day 14 PP population; a sub-set of the
Day 3 PP population including patients that completed all visits
during the study.
The null hypothesis was that there would be no difference in the
primary endpoint (mean time to PC90) between CPG2DDS
alone and CPG2DDS plus artesunate at each of the three doses.
The treatment difference was calculated from the mean values
of time to PC90. The principal analysis of mean time to PC90 was
performed for the subjects with confirmed 90% reduction of
parasitemia by 72 h based on a logistic model. This approach was
taken as it was not feasible to draw blood samples more frequently
and yet it was desirable to try to determine the time to PC90 that
likely occurs between sampling time points. For each subject,
observed parasite count data from 0272 h were log-transformed.
A logistic model was used to estimate the change in parasite count
between observations. The logistic curve had the following form:
y = a+l/(1+e2b(x2m)) where a= the lower asymptote, a+l= the
upper asymptote, b= the parasitemia reduction rate, m= the time
of maximum rate of reduction (i.e. point of inflexion), x = time
from first dose (in hours); y = log[1+P(time= x)] and (P= parasite
count), hence P= ey–1. The model of best fit was selected for each
subject by two independent statisticians blinded to treatment
group based on a set of pre-defined evaluation criteria: possible
data errors; outliers affecting model fit and whether to exclude
them; estimated modeled baseline and fit of model in baseline
region; estimate of PC90 and fit in these regions; and closeness of
model fit with observed data. Any subjects where the logistic curve
fitted to derive time to PC90 was not reliable were omitted in
order to preserve the integrity of the analysis, termed ‘poor model
fit’. Poor model fit was categorized as: the model being inadequate
to fit to the data; there being insufficient data to fit to the model; or
the subject not achieving PC90 by 72 h based on the model. The
mean time to PC90 was determined from the derived times to
PC90s of the available subjects.
In addition to the logistic model-based approach, the time to
PC90 based strictly on the observed parasite counts was conducted
as a sensitivity analysis. The aim of the sensitivity analysis was to
validate and reinforce the principal analysis as described above.
Comparisons were made across treatment using analyses of
covariance weighted according to stratification by gender and
center in adult subjects and separately in children stratified by age
group at baseline: 12,2, 22,3, 32,4, 42,5 or 52,10 years
(120 months) (children were enrolled at one center only).
No adjustment for the multiple comparisons to the CPG–DDS
alone arm was made. However, in order to preserve the overall
significance level at 5%, a step-down closed testing procedure was
used whereby the 4 mg/kg artesunate group was compared to
CPG2DDS alone and only if there was a statistically significant
difference at the 5% level was the 2 mg/kg compared with
CPG2DDS alone; only if this showed a significant difference was
the 1 mg/kg dose compared with CPG2DDS alone.
The study was powered for the primary analysis. Additional
analyses were presented for descriptive purposes, and no further
adjustments for multiplicity have been implemented. Summary
statistics (mean, standard deviation, median, minimum, maxi-
mum) for parasite counts were tabulated by treatment group for
adults and children. The proportion of subjects with gametocytes
at each timepoint was also summarized along with 95%
confidence intervals. Analyses of the secondary endpoints of mean
time to PC50 and mean time to PC99 were conducted in a similar
manner to those performed for PC90.
The ITT population was used for safety analyses. Safety
analyses included summaries of the proportion of patients with
adverse events and serious adverse events by treatment group. For
laboratory parameters, summary statistics (mean, standard devi-
ation, median, minimum and maximum) for each timepoint were
presented by treatment group. In addition, the proportion of
CD vs. CD+ 3 Artesunate Doses
PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1779
subjects with decreases in hemoglobin ($2 g/dL and $4 g/dL)
was tabulated by treatment group.
Results
Participant flow
Participant flow for the adult and child groups is shown in
Figure 1. No data are available regarding the precise number of
patients screened for inclusion in this study, or the reasons for their
not being enrolled.
There were 116 adults enrolled in the study. The Malawi
centers contributed 62 patients; 14 were randomized to
CPG2DDS alone, and 17, 17 and 14 to +artesunate 1, 2 or
4 mg/kg, respectively. The Gambia center contributed 54 adult
patients, 15 randomized to CPG2DDS alone and 13 patients
each randomized to +artesunate 1, 2 or 4 mg/kg. All of the 107
children enrolled into the study were recruited from the Malawi
center.
All randomized subjects were included in the ITT population.
Reasons for withdrawal from the study are shown in Figure 1;
there were no apparent differences between the study arms for
adults or children.
Recruitment
The trial was conducted between June 2002 and October 2004
at the Queen Elizabeth Central Hospital, Blantyre and six local
health centers in Malawi and between September 2004 and
February 2005 at the AFPRC General Hospital, Farafenni, The
Gambia.
Baseline data
The baseline demographic and clinical characteristics of the
Day 3 PP population are shown in Table 1 and were very similar
to those of the ITT population.
For adults, the ratio of females to males was similar in all
treatment groups except the CPG–DDS +artesunate 4 mg/kg
group, where the ratio was 6:12. These results were consistent with
the 2:3 adult female:male randomization (Table 1).
For children, the median age in the CPG–DDS +artesunate
1 mg/kg group was 46 months, compared with 29241 months in
the other groups. The ratio of females to males was similar in all
treatment groups except the CPG–DDS +artesunate 2 mg/kg
group, where the ratio was 6:17 (Table 1).
Numbers analyzed
The number of patients analyzed in the Day 3 PP population
and the Day 14 PP population are shown in Figure 1. Across the
treatment groups 67279% of adult subjects completed all study
assessments to Day 3 and were included in the Day 3 PP
population and 57266% qualified for the Day 14 PP population.
Across the treatment groups, a higher proportion of children were
included in the Day 3 PP population (79292%) and Day 14 PP
population (68283%) compared to adults. Similar numbers of
patients were excluded from these analyses for each dose group;
reasons for exclusion are shown in Figure 1.
In addition, six patients were excluded from the principal
analysis due to ‘poor model fit’. These exclusions were decided by
statisticians blind to treatment group. Two adult patients (one in
the CPG2DDS and one in the +artesunate 2 mg/kg group) and
four children (two in the CPG2DDS, one in the +artesunate
1 mg/kg and one in the +artesunate 2 mg/kg group) were
excluded as the model was inadequate to fit their data. No patients
were excluded due to not achieving PC90 by 72 h. Patients
excluded from the principal analysis were included in the
sensitivity analysis.
Outcomes and estimation
Primary outcome: Mean time to PC90. For adults, in the
Day 3 PP population, the mean time to PC90 was 19.1 h with
CPG2DDS alone. Statistical analysis indicated a significant
decrease in mean time to PC90 between CPG–DDS alone and
the +artesunate 4 mg/kg (28.7 h; P=0.002), 2 mg/kg (28.4 h;
P=0.002) and 1 mg/kg (26.6 h; P=0.013) groups (Figure 2,
Table 2).
For children, in the Day 3 PP population, the mean time to
PC90 was 21.1 h with CPG2DDS alone. There was a significant
decrease in the mean time to PC90 versus CPG2DDS alone for
the +artesunate 4 mg/kg (27.4 h; P=0.010) and the 2 mg/kg
(26.4 h; P=0.020) groups (Figure 2, Table 2). The reduction in
mean time to PC90 with 1 mg/kg artesunate of 23.3 h versus
CPG2DDS alone was not statistically significant (P=0.222)
(Table 2).
A sensitivity analysis was performed for the primary endpoint
based on observed parasite count data, including subjects who had
a poor model fit or insufficient data. As expected, mean values of
time to PC90 based on observed timepoints were higher than in
the principal analysis using the model-based approach (Table 2).
Outcomes were similar to the principal analysis except that in the
sensitivity analysis mean time to PC90 for adults receiving
CPG2DDS +artesunate 1 mg/kg was not significantly different
from CPG2DDS alone (treatment difference 26.2 h; P=0.057)
(Table 2). An analysis of outcomes for mean time to PC90 for the
Day 14 PP and ITT populations was consistent with those of the
Day 3 PP analysis (Table 2).
Secondary outcomes: Parasite viability. In adults at 12 h
after the first dose of study drug, mean parasite viability was 12.4%
in the CPG2DDS group. There was a significant decrease in
viability observed for the +artesunate 4 mg/kg (212.4%;
P=0.024) and 2 mg/kg (212.2%; P=0.011) groups versus
CPG–DSS alone (Table 3). However, there was no significant
difference for the +artesunate 1 mg/kg group versus CPG2DDS
alone (210.2%; P=0.104).
In children, the mean parasite viability with CPG2DDS alone
was 71.2% at 12 h. All artesunate combinations significantly
reduced the number of viable parasites at 12 h versus CPG–DDS
alone: by 268.6% (P=0.0004), 268.1% (P=0.0002) and
257.3% (P=0.0021) for the +artesunate 4, 2, and 1 mg/kg
groups, respectively (Table 3).
Secondary outcomes: Mean time to PC50 and PC99. In
adults, for the Day 3 per-protocol population, the mean time to
PC50 for CPG2DDS alone was 13.3 h (SD610.8 h). Statistical
analysis showed that in adults, addition of artesunate 4 mg/kg or
2 mg/kg resulted in a significant reduction in mean time to PC50
versus CPG2DDS alone; treatment difference 25.4 h (P=0.025)
and 25.9 h (P=0.012), respectively (Figure 3a). There was no
significant effect of +artesunate 1 mg/kg versus CPG2DDS alone
(treatment difference 24.5 h; P=0.054).
In children, the mean time to PC50 was 17.0 h (SD69.0) for
CPG2DDS alone. As for adults, in children the +artesunate
4 mg/kg and +artesunate 2 mg/kg groups had a significantly
shorter mean time to PC50 than CPG2DDS alone; treatment
difference 29.0 h (P=0.001) and 27.4 h (P=0.005), respectively
(Figure 3b). There was no significant effect on mean time to PC50
of adding 1 mg/kg artesunate versus CPG2DDS alone in either
adults or children (treatment difference 24.5 h; P=0.089).
The mean time to PC99 in adults with CPG2DDS alone was
25.0 h (SD611.5) (Figure 3a). There was a significant reduction in
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Figure 1. Trial profile of the study and patient flow for a) adults and b) children. ITT = intent to treat population; PP =per-protocol
population.
doi:10.1371/journal.pone.0001779.g001
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mean time to PC99 with +artesunate 4 mg/kg (212.8 h;
P=,0.001), 2 mg/kg (211.4 h; P=,0.001) and 1 mg/kg
(29.1 h; P=0.002) versus CPG2DDS alone.
The mean time to PC99 in children with CPG2DDS alone was
24.5 h (SD69.8) (Figure 3b). In contrast to adults, in children a
significant decrease in mean time to PC99 versus CPG2DDS
alone was observed only for the +artesunate 4 mg/kg group
(29.0 h; P=0.018).
Secondary outcomes: Gametocyte prevalence. In adults,
the percentage of gametocytemic patients in the CPG–DSS alone
group increased during the study to a maximum of 29.4% of
patients assessed at Day 14 (Figure 4). In the +artesunate 1 mg/kg
group, the proportion of patients with gametocytes was increased
versus Day 0 (4.5%) at both Day 7 (10.5%) and Day 14 (5.6%). For
the +artesunate 2 mg/kg group, there was small increase in
patients with gametocytes at Day 3 (5.0%) versus Day 0 (0%),
though gametocytes were absent at Days 7 and 14. The
+artesunate 4 mg/kg dose completely suppressed gametocytes
throughout the study.
In children, the percentage of gametocytemic patients in the
CPG–DDS group increased during the study to a maximum of
47.1% at Day 14 (Figure 5). In the +artesunate 1 mg/kg group,
the proportion of patients with gametocytes increased throughout
the study to a maximum of 8.7% at Day 14. In the +artesunate
2 mg/kg group, gametocytes were present in 18.2% of patients at
Day 3 versus 13.6% at Day 0, though no gametocytes were
detected at Day 7 or 14. In the +artesunate 4 mg/kg group,
despite a high Day 0 proportion of gametocytemic patients
(23.8%), gametocyte carriage was reduced at each sampling point,
achieving 0% at Day 14.
Secondary outcomes: Treatment failures. The trial was
underpowered for statistical analysis of clinical endpoints. Using
the modified WHO 2002 definitions [20], based on the Day 14 PP
population there were only three failures: one adult and two
children2all received CPG–DDS alone (Table 4). At 14 days, the
ACPR and ACPRp were identical as all failures were
recrudescences, though one child had a recrudescence plus a
new infection. A further child in the CPG2DDS +artesunate
4 mg/kg group had an extra visit recorded with recrudescence
plus new infection at Day 21.
Owing to the wide confidence intervals, there were no clear
differences in treatment failures observed between the artesunate
dose groups and CPG–DDS alone in either adults or children or
between adults and children (Table 4).
Ancillary analyses
Compliance with medication. The number of patients in
the ITT population in whom the initial dose or re-dose of study
drug(s) was successful on all 3 days (administration compliance)
was 94.2% (210/223). For adults, administration compliance was
89.7%, 96.7%, 90.0%, 96.3% for the CPG2DDS only, and
+artesunate 1, 2 and 4 mg/kg groups, respectively; corresponding
numbers for children were 95.8%, 96.6%, 100% and 89.3%,
respectively.
Overall, in the ITT population, 91.9% (205/223) of subjects
were totally compliant, i.e. the initial dose or re-dose of study
drug(s) was successful on all 3 days and they received the correct
mg/kg/day target doses of study drug as per the randomization
schedule. For adults, 89.7%, 96.7%, 86.7% and 96.3% of patients
were totally compliant in the CPG2DDS only, and +artesunate 1,
2 and 4 mg/kg groups, respectively; corresponding numbers for
children were 95.8%, 93.1%, 96.2% and 82.1%, respectively.
Adverse events
This study was not powered to conduct formal comparisons of
safety between treatment arms. The observed nature and
incidence of adverse events were similar between the groups
(Table 5) and were consistent with the known profile of
CPG2DDS. The most common adverse events in adults were
nausea, reticulocytosis and acquired methemoglobinemia and in
children were reticulocytosis, anemia and acquired methemoglo-
binemia (Table 5).
There were some differences in the reporting of adverse events
by center (for adults). In Malawi, adverse events were recorded for
11/14 (78.6%) of adults receiving CPG2DDS alone and 11/17
(64.7%), 12/17 (70.6%) and 11/14 (78.6%) for those receiving 1, 2
or 4 mg/kg of artesunate respectively. In The Gambia, the
number of adverse events reported was much lower than in
Malawi: 7/15 (46.6%) patients for CPG2DDS alone and 5/13
(38.5%), 3/13 (23.1%) and 4/13 (30.7%) for those receiving 1, 2 or
4 mg/kg of artesunate respectively. However, in both centers
there were no apparent differences in the nature or incidence of
adverse events between the CPG2DDS alone group and the
artesunate groups.
Table 1. Baseline demographic and clinical characteristics of the Day 3 per-protocol population.
Characteristic CPG–DDS +artesunate 1 mg/kg +artesunate 2 mg/kg +artesunate 4 mg/kg
Adults N= 23 N= 22 N=22 N=18
Median age, years (range) 27.0 (18255) 25.0 (18250) 27.0 (21259) 28.0 (18258)
Male sex, n (%) 12 (52.2) 12 (54.5) 13 (59.1) 12 (66.7)
Median weight, kg (range) 53.8 (44.5266.0) 56.3 (42.0281.0) 53.5 (44.0276.0) 54.9 (42.5276.0)
Median pre-dose parasitemia, mL21 (inter-
quartile range)
26912 (14854:44120) 16279 (10451:35707) 22828 (15366:30121) 22527 (13537:49021)
Children N= 22 N= 25 N=23 N=22
Median age, months (range) 29.0 (142112) 46.0 (132116) 36.0 (132118) 40.5 (152121)
Male sex, n (%) 13 (59.1) 13 (52.0) 17 (73.9) 12 (54.5)
Median weight, kg (range) 10.9 (7.9229.8) 13.4 (7.4225.6) 12.8 (8.2235.8) 12.4 (7.3226.2)
Median pre-dose parasitemia, mL21 (inter-
quartile range)
44973 (34596:56027) 37730 (30757:50656) 45880 (30800:59307) 39972 (24480:56022)
NB: All patients were black African.
doi:10.1371/journal.pone.0001779.t001
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Two non-fatal treatment-emergent serious adverse events were
observed in two adults (one each in the +artesunate 4 and 2 mg/kg
groups) and six were observed in three children (two in the
CPG2DDS group and one in the +artesunate 4 mg/kg group). In
addition, one child experienced vomiting before and after dosing
with study treatment and required an additional night in hospital.
Six of the serious adverse events were not thought to be related to
study medication and included one case of sepsis in an adult
patient and in the child group two cases of sepsis and one each of
malnutrition, malaria and cerebral malaria.
Two of the serious adverse events were thought to be related to
study drug. One adult case of severe hemolytic anemia in the
+artesunate 2 mg/kg group presented at Day 9 with a hemoglobin
concentration of 6.6 g/dL (baseline 15.4 g/dL), was treated with
two units of blood and the patient recovered. However, this
patient subsequently went on to experience anaphylactic shock
(day 14 after recruitment) which resulted in death. The
investigator considered this event to be related to herbal
preparations that the subject had taken and not to study
medication.
The second drug-related event was a report of anemia in a
10 year old child in the +artesunate 4 mg/kg group who presented
with a hemoglobin concentration of 3.8 g/dL at Day 7 (baseline
12.0 g/dL), was treated with blood transfusion and antibiotics and
recovered.
No artesunate dose-related changes in laboratory blood
parameters were noted (Table 6). There was a progressive
decrease in hemoglobin concentration through Day 3, 7 and 14
in adults (Table 6). However, adult reticulocyte counts on Day 7
and 14 were increasing, suggesting that if patients had been
followed up to Day 28, hemoglobin concentration may have
corrected to baseline (Table 6). At Day 7, 45.2% (42/93) of all
adults had a decrease in hemoglobin concentration from baseline
of $2 g/dL and 17.2% (16/93) had a decrease of $4 g/dL
(Table 7). Day 14 assessments were only measured if clinically
indicated. Of the patients with assessments at Day 14, 38.1% (16/
42) had $2 g/dL reduction in hemoglobin concentration from
baseline, though the proportion with a decrease of $4 g/dL had
fallen to 7.1% (3/42) (Table 7).
Baseline hemoglobin levels were lower in children than in
adults, and decreased further at Day 3 (Table 6). However, in
contrast to adults, there was a rebound in hemoglobin levels in
children at Day 7 and 14 (Table 6). When combining all child
groups, 10.5% (10/95) of children had a decrease in hemoglobin
concentration from baseline of $2 g/dL and 2.1% (2/95) had a
decrease of $4 g/dL at Day 7, though by Day 14 only two
children had a decrease in hemoglobin concentration from
baseline of $2 g/dL and none had a decrease $4 g/dL (Table 7).
All subjects experienced a rise in methemoglobin levels by Day
3, though in all subjects this had decreased to approximately
baseline levels by Day 7 (Table 6). There were no symptoms
attributable to methemoglobinemia. The highest methemoglobin
level recorded was 15.9% in an adult patient receiving CPG2DSS
+artesunate 2 mg/kg and the highest recorded level in a child was
14.2% (received CPG2DDS alone).
Discussion
Interpretation
The addition of artesunate to CPG–DDS demonstrated
advantages over CPG–DDS alone for the primary efficacy
endpoint (mean time to PC90) and for the majority of secondary
endpoints in the adult group.
This study achieved very accurate artesunate dosing to the
target groups. However, the final fixed dose triple combination
tablet needs to allow for a wider range of eventual mg/kg doses
based on the weight of the individual patient. For example, for a
target dose of 2 mg/kg artesunate, some patients would be
expected to actually receive only 1 mg/kg. Thus, the outcome
decision matrix was constructed conservatively; i.e. to confidently
select the +artesunate 2 mg/kg target dose for the fixed dose
combination, the +artesunate 1 mg/kg dose would have needed to
be statistically different from CPG–DDS alone for all endpoints.
In children, +artesunate 1 mg/kg was not significantly different
from CPG2DDS alone for mean time to PC90 (the primary
endpoint) and for mean time to PC50 and PC99. In adults,
Figure 2. Primary efficacy outcome: mean time to PC90 (695%
confidence intervals) in the Day 3 per-protocol population for
(a) adults and (b) children. *P #0.05 versus CPG2DDS alone; **P
#0.01 versus CPG–DDS alone.
doi:10.1371/journal.pone.0001779.g002
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although +artesunate 1 mg/kg was significantly different from
GPG2DDS alone for the mean time to PC90 (the primary
endpoint) in the principal (logistic model) analysis, this was not
supported by the sensitivity analysis using observed data. In
addition, +artesunate 1 mg/kg was not significantly different from
CPG2DDS alone for mean time to PC50 in adults. Although
patient numbers were small there was no statistical difference in
the effect on parasite viability of +artesunate 1 mg/kg versus
CPG2DDS alone in adults. There were no apparent differences
in the safety profile of CPG2DDS alone or in combination with
artesunate in this study and no artesunate dose-related changes in
laboratory parameters were observed. Thus, 4 mg/kg artesunate
was selected as the dose to be combined with CPG2DDS in the
fixed dose combination tablet for further investigation in Phase III
studies.
Generalizability
We examined the differential effect of adding artesunate
to CPG2DDS alone. This study was powered to determine the
effect of the artesunate doses versus CPG2DDS alone and
not to compare the different artesunate doses against each other.
In this study a mean time to PC90 of 9 h was assumed as the
difference between the artesunate groups and CPG2DDS alone.
When comparing between artesunate doses, we would expect a
smaller difference in mean time to PC90, and as the artesunate
dose increases so the planned difference decreases. As a
consequence, the required sample size increases for each
comparison to the point where a study of this type would be
impractical at Phase II.
The 14 day follow up used in this study was sufficient to
demonstrate differences between the artesunate groups and
CPG2DDS alone for the parasitological endpoints. The phase
III studies with CDA will include a 28-day follow up, based on
recent WHO guidelines [18], and will compare clinical endpoints
in a conventional comparative trial. These trials will assume equal
clinical efficacy (non-inferiority) between CDA and either
CPG2DDS or artemether2lumefantrine and include over 2000
patients in total.
The patients in this study were not selected to be necessarily
representative of the typical patient presenting with malaria in this
setting. The inclusion and exclusion criteria were stringent and
selected particularly to identify patients in whom the necessary
data for parasitiological endpoints could be collected in order to
achieve the study aim, i.e. to identify the effective dose of
artesunate. In particular, the cut-offs for parasite density were
narrower than commonly used in studies that use ACPRp as a
primary outcome. In children, an initial parasite density of at least
25,000 mL21 was used; lower parasite counts may have resulted in
such rapid parasite clearance so as to preclude any comparison of
artesunate effect. The maximum parasite load of 100,000 mL21
has been used throughout the CPG2DDS and CDA development
plans. This is a compromise between having a robust test of the
drug while minimizing the number of patients that might have a
parasite count exceeding 250,000 mL21 at any point, i.e. the safety
cut off whereby a patient must be withdrawn from the study.
The narrow selection criteria in this study and the requirement
to stay in hospital contributed to the screening of a very large
number of patients. Unfortunately, recording all the patients that
Table 2. Mean time to PC90 (primary endpoint) for the Day 3 per-protocol (PP) population (principal analysis population) and
supportive analyses: sensitivity analysis on the Day 3 PP population and outcomes for the Day 14 PP population and the intent to
treat (ITT) population.
Analysis Adults Children
CPG–DDS
+artesunate
1 mg/kg
+artesunate
2 mg/kg
+artesunate
4 mg/kg CPG–DDS
+artesunate
1 mg/kg
+artesunate
2 mg/kg
+artesunate
4 mg/kg
Day 3 PP populationa n= 22 n= 22 n = 21 n= 18 n = 20 n= 24 n = 22 n = 22
Mean time to PC90, h6SD 19.1612.8 12.567.6 10.766.2 10.364.2 21.169.1 17.7610.6 14.467.2 12.867.1
Treatment difference (95% CI) 2 26.6 (211.8,
21.5)
28.4 (213.6,
23.2)
28.7 (214.1,
23.2)
2 23.3 (28.6, 2.0)26.4 (211.7,
21.0)
27.4 (212.9,
21.8)
P value 2 0.013 0.002 0.002 2 0.222 0.020 0.010
Sensitivity analysis n= 23 n= 22 n = 22 n= 18 n = 22 n= 25 n = 23 n = 22
Mean time to PC90, h6SD 20.2617.1 13.968.8 11.866.0 11.965.0 26.3614.9 20.8612.0 15.268.3 15.167.4
Treatment difference (95% CI) 2 26.2 (212.6,
0.2)
28.5 (214.9,
22.1)
28.1 (214.9,
21.3)
2 25.0 (211.7,
1.6)
211.0 (217.4,
24.0)
210.0 (217.0,
23.1)
P value 2 0.057 0.010 0.020 2 0.134 0.002 0.005
Day 14 PP population n= 18 n= 18 n = 17 n= 17 n = 18 n= 23 n = 19 n = 19
Mean time to PC90, h6SD 20.0612.9 12.966.8 10.966.4 10.164.2 21.469.5 18.5610.2 14.267.8 13.166.3
Treatment difference (95% CI) 2 27.3 (212.9,
21.7)
28.9 (214.6,
23.2)
29.8 (215.5,
24.1)
2 22.8 (28.3, 2.8)26.6 (212.3,
20.9)
27.4 (213.3,
21.5)
P value 2 0.012 0.003 0.001 2 0.322 0.023 0.015
ITT population n= 26 n= 29 n = 27 n= 26 n = 21 n= 28 n = 24 n = 25
Mean time to PC90, h6SD 19.7612.6 12.067.3 10.165.9 9.564.1 21.469.0 16.7610.4 14.667.0 12.367.2
Treatment difference (95% CI) 2 27.7 (212.1,
23.3)
29.5 (214.0,
25.1)
210.2 (214.7,
25.8)
2 24.4 (29.3, 0.5)26.0 (211.1,
20.9)
27.9 (213.1,
22.7)
P value 2 0.0007 ,0.0001 ,0.0001 2 0.078 0.022 0.003
an =Day 3 PP population minus six patients (two adults, four children) with ‘poor model fit’ due to the model being inadequate to fit their data.
P values that are statistically significant are in italics to aid comparison.
doi:10.1371/journal.pone.0001779.t002
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Figure 3. Results for Day 3 per-protocol population for mean time to PC50 and mean time to PC99 for (a) adults and (b) children. *P
#0.05 versus CPG2DDS alone; **P #0.01 versus CPG–DDS alone. Five adults (two in the CPG2DDS group, two in the +artesunate 1 mg/kg group
and one in the +artesunate 2 mg/kg group) and 14 children (three from the CPG2DDS group, and five, three and three from the +artesunate 1, 2 and
4 mg/kg groups, respectively) were excluded from the mean time to PC50 analysis due to poor model fit. Seven adults (five in the CPG2DDS group,
and one each in the +artesunate 1 mg/kg and 2 mg/kg groups) and five children (two from the CPG2DDS group, two from the +artesunate 1 mg/kg
and one from the +artesunate 2 mg/kg group) were excluded from the mean time to PC99 analysis due to poor model fit.
doi:10.1371/journal.pone.0001779.g003
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were screened and the reasons for not enrolling them in the study
was not practical at all the centers. We believe that screening data
would have confirmed that the study patient population was not
generally representative of patients presenting with malaria.
Patients in this study were required to stay in hospital for four
days and three nights. This had a negative impact on recruitment
of this study in Malawi, in particular for adults, necessitating the
opening of a second center in The Gambia. As a result, no discrete
analysis by center was planned, though center was included in the
model for analysis of efficacy. Adverse events were reported less
frequently for all treatment groups (for adults) at The Gambia
study center compared with the Malawi center. These adverse
events were recorded based on the discretion of the investigator,
and the observed differences could reflect different clinical
perspectives or cultural differences between the two sites.
However, as there were no differences in the safety outcomes for
CPG2DDS versus the artesunate groups for each center,
differences between centers did not impact the overall safety
outcome of the study.
Patients in this study were excluded if they had overt signs of
immunosuppression, but no HIV testing was performed. In 2006,
the estimated proportion of the adult population living with HIV
was 14.1% in Malawi and 2.4% in The Gambia and in 2003, it
was 14.2% and 2.2%, respectively [22]. A study conducted at the
Malawi study site found that HIV positive adults with CD4 cell
counts ,200 cells/mm3 had a higher incidence of malaria than
those with counts .500 cells/mm3 though the prevalence of
malaria was not influenced by CD4 count [23]. Thus, it is possible
Figure 4. Adults: Percentage of patients who were gametocytemic in the Day 3 per-protocol population at each scheduled
assessment time.
doi:10.1371/journal.pone.0001779.g004
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that the proportion of HIV-infected individuals in the study who,
by definition, had reported to hospital with malaria, may be higher
than in the general population. The effect of the different HIV
prevalence for the two centers is unknown. To address this, as well
as other possible confounders, ‘center’ was included in the analysis
of covariance in the efficacy model. However, it is important to
note that, as the efficacy conclusions of the study are based only on
data from children, all of whom were recruited from Malawi, any
effect on efficacy between the centers would not have changed the
outcome of this study.
For children, the median age in the CPG–DDS +artesunate
1 mg/kg group was 46 months, compared with 29241 months in
the other groups. This difference may have affected the results as
younger children tend to get more severe malaria. However, the
direction of any effect would have been to make 1 mg/kg
artesunate appear better than it would have given a more equal
balance of ages across the groups, and so this would not have
affected the outcome of the decision matrix for dose selection.
When this trial was conceived, it was unknown whether the
sparse blood sampling achievable in children would be sufficient to
show any treatment differences. An adult group was, therefore,
included to provide a more closely sampled data set. However, it
seems that despite less frequent sampling in children, the
parasitological endpoints were sensitive enough to show differenc-
es between the artesunate groups when each was compared to
CPG2DDS alone.
It was hoped that parasite viability would provide a robust key
secondary endpoint to inform interpretation of the mean time to
Figure 5. Children: Percentage of patients who were gametocytemic in the Day 3 per-protocol population at each scheduled
assessment time.
doi:10.1371/journal.pone.0001779.g005
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PC90 data. However, a systematic error in the technique that was
later corrected meant that the number of patients included in this
analysis was less than we had planned; 40/85 (47.1%) of adults
and 13/92 (14.1%) of children were excluded. Thus, the
confidence intervals around the mean treatment difference were
too large to make relevant comparisons of the differential effect of
the artesunate doses versus CPG2DDS alone. However, the data
are still interesting. As would be expected, parasite viability did
show the potent schizonticidal activity of artesunate, demonstrat-
ing the value of adding this drug to the already clinically effective
CPG2DDS combination. Unexpectedly, even for the
CPG2DDS group, where no effect on parasite viability would
be anticipated from this anti-folate inhibitor, parasite viability in
adults was only 12.4% versus 71.2% for children. It may be that in
adults there is some residual, long-lived immune-related process
contributing to the impairment of ex-vivo parasite viability. This
observation requires further investigation.
Overall evidence
It was not practical/ethically justifiable to include an artesunate
monotherapy arm in the current study due to the long (7-day)
course of treatment required and the risk of developing resistance
to artemisinins. The ACPRp at Day 28 for 4 mg/kg artesunate
monotherapy has been reported as 72% (36/50) for 3-day dosing
[24], and 90% (45/50) for 5-day dosing in Gabonese children
(#15 years) [25]. In the current study, the ACPRp of CPG2DDS
plus 4 mg/kg artesunate was 100% at Day 14, indicating that
combining artesunate with CPG2DDS allows effective short-
course therapy.
A number of clinical studies have evaluated artesunate
combination therapy in the treatment of uncomplicated falci-
parum malaria in African children. However, data comparing
different doses of artesunate within combination therapy have
been lacking.
A study conducted in Thailand by Angus et al. in patients of at
least 15 years of age found that 2 mg/kg artesunate was the lowest
dose that, on average, achieved maximum effects on parasite
clearance outcomes [7]. However, these authors also pointed out
that there was considerable pharmacokinetic and pharmacody-
namic variance between individuals and that a dose of 4 mg/kg
artesunate would be the minimum required to ensure a maximal
effect in all individuals [7]. Similarly, in the current study, mean
effects of +artesunate 2 mg/kg and 4 mg/kg versus CPG2DDS
were similar for all efficacy outcomes in adults. However, to allow
for dosing variations when using a fixed dose combination and the
inter-subject pharmacokinetic variability seen with artesunate, the
decision matrix selected the dose above that which showed, on
average, acceptable efficacy. This strategy aims to reduce the
Table 3. Ex-vivo parasite viability at 12 h after the first dose of study drug in the Day 3 per-protocol population.
Parasite viability CPG–DDS +artesunate 1 mg/kg +artesunate 2 mg/kg +artesunate 4 mg/kg
Adultsa n= 14 n = 6 n = 16 n = 9
Mean viability6SD, % (range) 12.4621.9 (0259) 1.262.9 (027) 0 (020) 0 (020)
Treatment difference (95% CI) 2 210.2 (222.6, 2.2) 212.2 (221.3, 23.0) 212.4 (223.1, 21.7)
P value 2 0.1036 0.0106 0.0239
Childrena n= 19 n = 19 n = 21 n = 20
Mean viability6SD, % (range) 71.26104.0 (02416) 13.5631.7 (02126) 1.565.3 (0223) 0.260.7 (023)
Treatment difference (95% CI) 2 257.3 (293.1, 221.6) 268.1 (2103.2, 232.9) 268.6 (2105.1, 232.1)
P value 2 0.0021 0.0002 0.0004
an =Day 3 per-protocol population minus patients excluded due to lack of a valid parasite viability assessment at 12 h61 h.
doi:10.1371/journal.pone.0001779.t003
Table 4. Treatment responses at Day 14 based on WHO 2002 definitions [20] (Day 14 per-protocol population).
Treatment response, n (%) CPG–DDS +artesunate 1 mg/kg +artesunate 2 mg/kg +artesunate 4 mg/kg
Adults N= 19 N= 18 N=17 N= 17
Early treatment failure 0 0 0 0
Late clinical failure 0 0 0 0
Late parasitological failure 1 (5.3) 0 0 0
ACPRp [95% CI] 18 (94.7) [74.0, 99.9] 18 (100) [81.5, 100] 17 (100) [80.5, 100] 17 (100) [80.5, 100]
Children N= 20 N= 24 N=20 N= 19
Early treatment failure 0 0 0 0
Late clinical failure 2 (10.0) 0 0 0
Late parasitological failure 0 0 0 0
ACPRp [95% CI] 18 (90.0) [68.3, 98.8] 24 (100) [85.8, 100] 20 (100) [83.2, 100] 19 (100) [82.4, 100]
ACPRp = adequate clinical and parasitological response corrected for polymerase chain reaction genotyping, i.e. including patients ACPR at Day 14 plus those who were
late clinical and/or parasitological failures but with a new infection and no recrudescence.
doi:10.1371/journal.pone.0001779.t004
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potential for resistance emergence and spread by achieving
maximal parasite reduction in as many treatments as possible.
There appeared to be a dose2response effect in this study for
parasite clearance with artesunate up to 4 mg/kg in children, but
not in adults, though this was not tested formally. Children have
immature immune systems and more limited exposure to P.
falciparum and are thus a more sensitive population in which to test
the effect of different artesunate doses. Children are also a more
vulnerable population clinically and it is important to minimize the
possibility of breakthrough parasitemia and recrudescence in this
group. Although the children in the study were all over 13 months
of age, we believe the differences in outcome observed between
adults and children were due primarily to differences in
immunological response to P. falciparum. This is supported by the
observation of far higher levels of parasite viability in children than
in adults at 12 h after the first dose of study treatment for
CPG2DDS alone and the need for higher doses of artesunate to
effectively suppress parasite viability in children versus adults. A
subsequent study is planned to determine the safety and efficacy of
CDA in children of #12 months.
Safety
Hematological effects are a known adverse event associated with
the DDS component [26]. DDS reduces erythrocyte lifespan,
causing methemoglobinemia and hemolysis, which may be
affected by dose and duration of exposure [26]. These effects
are usually mild and self-limiting, as observed for the majority of
patients in this study and previously [15]. The frequency of
hemolysis requiring blood transfusion in this clinical trial (0.89%
[2/223]) is similar to that observed in a previous clinical trial of
CPG2DDS alone in five African countries in which 10/1480
patients (0.67%) had a serious adverse event of hemolysis [15].
Erythrocyte survival is further shortened in subjects given DDS
who are glucose-6-phosphate (G6PD) deficient [26]. In July 2004,
a WHO technical consultation recommended that, as an interim
measure, patients should be screened for G6PD deficiency before
being given CPG2DDS, though G6PD-deficient patients should
not necessarily be excluded from clinical trials [27]. The current
study was started before this recommendation, against a
background of widespread use of DDS without G6PD screening.
It is, therefore, unknown whether the two cases of hemolysis
reported here were in G6PD-deficient patients. To determine any
significant differences in hematological effects for DDS between
G6PD normal and deficient individuals would require a large
study to evaluate rare events in this subpopulation; approximately
2500210,000 patients depending on the prevalence of G6PD
deficiency. To further inform the hematological safety profile of
CDA, G6PD testing is being conducted in CDA Phase III studies
including as comparators CPG2DDS alone and artemether2lu-
mefantrine.
Although this study was not powered to make a formal
assessment of safety outcomes between the treatment groups,
these did not appear to be influenced by artesunate dose. Safety
outcomes will be investigated more fully in a phase III trial of
CDA versus CPG2DDS alone.
Conclusion
Artemisinin-derived compounds, such as artesunate, are
included in combination therapy to rapidly reduce parasite load,
for their gametocytocidal effect2potentially reducing transmis-
sion2 and to preserve antimalarial effectiveness by reducing the
potential for the development of parasite drug resistance.
Clinically, they reduce fever rapidly. However, where the other
components of combination therapy are effective, artemisinins
have little impact on the WHO definition of adequate clinical and
parasitological response at Day 14 or Day 28.
This study demonstrates the use of parasitemia-related out-
comes, specifically mean time to PC90, in a clinical trial to make
Table 5. Treatment emergent investigational drug-related adverse events reported during the study and the most common
adverse events reported in $10% of patients in any treatment group for the intent to treat (safety) population.
Preferred term, n (%) Adults Children
CPG–DDS
+artesunate
1 mg/kg
+artesunate
2 mg/kg
+artesunate
4 mg/kg CPG–DDS
+artesunate
1 mg/kg
+artesunate
2 mg/kg
+artesunate
4 mg/kg
N=29 N=30 N=30 N=27 N=24 N=29 N=26 N=28
Any adverse event 10 (34.5) 10 (33.3) 11 (36.7) 10 (37.0) 19 (79.2) 19 (65.5) 21 (80.8) 16 (57.1)
Reticulocytosis 2 (6.9) 3 (10.0) 3 (10.0) 1 (3.7) 7 (29.2) 11 (37.9) 9 (34.6) 7 (25.0)
AM 4 (13.8) 0 2 (6.7) 3 (11.1) 3 (12.5) 3 (10.3) 2 (7.7) 5 (17.9)
Anemia 0 1 (3.3) 0 2 (7.4) 6 (25.0) 1 (3.4) 6 (23.1) 6 (21.4)
Vomiting 4 (13.8) 2 (6.7) 2 (6.7) 0 3 (12.5) 2 (6.9) 3 (11.5) 1 (3.6)
Abdominal pain 3 (10.3) 1 (3.3) 2 (6.7) 0 4 (16.7) 0 2 (7.7) 3 (10.7)
Nausea 4 (13.8) 4 (13.3) 3 (10.0) 2 (7.4) 1 (4.2) 0 0 1 (3.6)
Anorexia 0 2 (6.7) 2 (6.7) 1 (3.7) 3 (12.5) 2 (6.9) 4 (15.4) 0
Cough 0 1 (3.3) 1 (3.3) 2 (7.4) 4 (16.7) 3 (10.3) 2 (7.7) 1 (3.6)
Thrombocythemia 0 0 0 0 1 (4.2) 3 (10.3) 0 1 (3.6)
AST increased 1 (3.4) 1 (3.3) 0 1 (3.7) 1 (4.2) 2 (6.9) 1 (3.8) 5 (17.9)
Diarrhea 1 (3.4) 1 (3.3) 1 (3.3) 0 2 (8.3) 3 (10.3) 1 (3.8) 2 (7.1)
Thrombocytopenia 0 0 0 0 1 (4.2) 5 (17.2) 4 (15.4) 3 (10.7)
Leukocytosis 0 0 0 0 1 (4.2) 0 3 (11.5) 0
AM, acquired methemoglobinemia; AST, aspartate aminotransferase.
doi:10.1371/journal.pone.0001779.t005
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decisions regarding the appropriate artesunate dose to use with an
already clinically effective antimalarial combination therapy
(CPG2DDS). Based on the findings of this study, Phase III
clinical trials with CDA are progressing with a fixed dose
combination of 2 mg/kg CPG, 2.5 mg/kg DDS and 4 mg/kg
artesunate.
Supporting Information
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0001779.s001 (0.74 MB
PDF)
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001779.s002 (0.05 MB
DOC)
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Table 6. Blood parameters where significant changes were observed during treatment for the intent to treat (safety) population.
Parameter Time point CPG–DDS +artesunate 1 mg/kg +artesunate 2 mg/kg +artesunate 4 mg/kg
n Mean6SD n Mean6SD n Mean6SD n Mean6SD
Adults
Hemoglobin (g/dL) Day 0 29 13.7362.16 30 13.4962.62 30 12.7162.41 27 13.3462.26
Day 3 25 12.5462.95 28 12.2062.64 25 12.2263.24 26 12.0762.22
Day 7 22 11.4462.68 27 11.6162.76 22 11.4162.49 22 11.3662.32
Day 14a 11 11.3262.39 13 10.7961.44 10 10.5761.80 8 9.5861.29
Reticulocyte count (%) Day 0 28 1.4761.78 29 1.3061.45 29 1.4561.91 27 1.4261.47
Day 3 25 1.2961.57 25 1.5561.82 23 1.0061.11 25 0.8560.92
Day 7 29 1.8462.80 24 2.7064.43 21 1.8461.53 21 2.7864.35
Day 14a 11 4.8863.25 12 3.1262.21 9 2.6560.69 7 4.1160.58
Methemoglobin (%) Day 0 19 0.4660.45 20 0.4860.35 22 0.3860.26 21 0.4460.37
Day 3 16 4.7565.02 17 2.6161.82 20 4.0464.49 19 4.7663.05
Day 7 15 1.0761.34 20 1.2360.82 16 0.9561.13 19 0.7460.37
Day 14a 6 0.7760.38 9 0.5760.30 4 0.2560.25 4 0.4360.34
Platelets (6109/L) Day 0 28 106.3652.9 30 101.8650.5 30 94.6647.5 27 109.8661.5
Day 3 25 113.2643.4 27 163.4667.2 25 149.1642.7 26 141.3663.4
Day 7 22 176.5679.6 27 227.3679.5 22 232.4666.4 22 232.5699.9
Day 14a 11 249.06105.8 12 257.26122.3 10 253.1674.0 7 218.6684.0
Children
Hemoglobin (g/dL) Day 0 24 9.0361.76 29 9.1261.48 25 9.1361.81 27 8.8961.42
Day 3 23 7.9762.01 27 8.5461.50 23 8.1661.66 23 8.2361.68
Day 7 23 8.4861.51 27 8.8761.35 23 8.6561.36 23 8.5261.34
Day 14a 20 9.7461.29 22 9.4861.18 18 9.7161.14 18 9.8461.35
Reticulocyte count (%) Day 0 23 3.5462.42 28 3.3262.15 25 3.0962.29 26 4.1763.33
Day 3 23 2.8562.25 23 3.8163.28 21 3.4462.23 21 2.5762.94
Day 7 21 6.7264.99 24 7.1264.79 18 6.8764.90 21 7.5567.58
Day 14a 20 7.9769.05 17 4.8066.30 16 3.9363.52 14 4.7464.11
Methemoglobin (%) Day 0 19 0.3960.31 25 0.4360.34 25 0.6360.58 27 0.3060.26
Day 3 21 2.2663.21 21 2.2662.16 21 2.4962.67 21 2.7063.43
Day 7 22 0.7961.46 26 0.4060.36 20 0.5060.40 22 0.4160.27
Day 14a 13 0.3860.28 16 0.3660.39 7 0.5360.46 11 0.3960.28
Platelets (6109/L) Day 0 24 140.8668.4 28 149.3686.2 25 126.6664.0 28 134.0686.9
Day 3 23 167.3672.6 26 204.86107.1 21 177.5698.7 24 157.2672.8
Day 7 22 253.06133.9 26 289.86152.9 23 282.0696.1 23 292.76109.7
Day 14a 20 280.66119.9 22 354.06153.5 17 258.06119.8 18 256.96108.9
aDay 14 values were obtained only if Day 7 values were abnormal.
doi:10.1371/journal.pone.0001779.t006
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